HLA-DR4 antigen inhibitor (ImmunoMolecular Therapeutics)

N/A

Report date: 2025/01/26 19:07:41
NME

Base Information

Drug NameHLA-DR4 antigen inhibitor (ImmunoMolecular Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHLA-DR antigens-associated invariant chain inhibitors
TargetsHLA-DR antigens-associated invariant chain
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImmunoMolecular Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunoMolecular Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A